Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments

ABSTRACT Bone marrow derived cells (BMDCs) have been shown to contribute in the tumor development. In vivo animal models to investigate the role of BMDCs in tumor development are poorly explored. We established a novel chimeric mouse model using as low as 5 × 106 GFP+ BM cells in athymic nude mice, which resulted in >70% engraftment within 14 d. In addition, chimera was established in NOD-SCID mice, which displayed >70% with in 28 d. Since anti-angiogenic therapies (AAT) were used as an adjuvant against VEGF-VEGFR pathway to normalize blood vessels in glioblastoma (GBM), which resulted into marked hypoxia and recruited BMDCs to the tumor microenvironment (TME). We exploited chimeric mice in athymic nude background to develop orthotopic U251 tumor and tested receptor tyrosine kinase inhibitors and CXCR4 antagonist against GBM. We were able to track GFP+ BMDCs in the tumor brain using highly sensitive multispectral optical imaging instrument. Increased tumor growth associated with the infiltration of GFP+ BMDCs acquiring suppressive myeloid and endothelial phenotypes was seen in TME following treatments. Immunofluorescence study showed GFP+ cells accumulated at the site of VEGF, SDF1 and PDGF expression, and at the periphery of the tumors following treatments. In conclusion, we developed a preclinical chimeric model of GBM and phenotypes of tumor infiltrated BMDCs were investigated in context of AATs. Chimeric mouse model could be used to study detailed cellular and molecular mechanisms of interaction of BMDCs and TME in cancer.

[1]  R. Knight,et al.  Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks. , 2015, Cancer letters.

[2]  P. Wen,et al.  Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma , 2014, Oncotarget.

[3]  I. Simeonova,et al.  In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies , 2014, Cellular and Molecular Life Sciences.

[4]  I. Simeonova,et al.  In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies , 2014, Cellular and Molecular Life Sciences.

[5]  A. Arbab,et al.  Myeloid Derived Suppressor Cells: Fuel the Fire , 2014, Biochemistry & physiology.

[6]  Bhanu P. Jena,et al.  Journal of Cellular and Molecular Medicine , 2014, Journal of Cellular and Molecular Medicine.

[7]  Xiao-li Zhang,et al.  Defective TGF-β signaling in bone marrow-derived cells prevents hedgehog-induced skin tumors. , 2014, Cancer research.

[8]  K. Aldape,et al.  Using the molecular classification of glioblastoma to inform personalized treatment , 2014, The Journal of pathology.

[9]  R. Sidman,et al.  CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis , 2013, Proceedings of the National Academy of Sciences.

[10]  Stephen L. Brown,et al.  Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study. , 2013, Translational oncology.

[11]  B. R. Achyut Impact of Microenvironment in Therapy-Induced Neovascularization ofGlioblastoma , 2013 .

[12]  Christina S. Leslie,et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.

[13]  Sarah E. Seton-Rogers Tumour microenvironment: Means of resistance , 2013, Nature Reviews Cancer.

[14]  Zhaoshi Jiang,et al.  An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy , 2013, Nature Medicine.

[15]  Jennie W. Taylor,et al.  Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. , 2013, Neuro-oncology.

[16]  F. Peale,et al.  Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF–induced neutrophil recruitment , 2013, Proceedings of the National Academy of Sciences.

[17]  J. Heymach,et al.  Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. , 2012, Neuro-oncology.

[18]  K. Connelly,et al.  eNOS deficiency predisposes podocytes to injury in diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[19]  W. Stetler-Stevenson,et al.  TIMP-2 Targets Tumor-associated Myeloid Suppressor Cells With Effects in Cancer Immune Dysfunction and Angiogenesis , 2012, Journal of immunotherapy.

[20]  A. Arbab Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. , 2012, Histology and histopathology.

[21]  H. Pan,et al.  Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. , 2012, Cancer research.

[22]  Luca Richeldi,et al.  Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. , 2011, The New England journal of medicine.

[23]  M. Chamberlain The paradoxical effect of bevacizumab in the therapy of malignant gliomas , 2011, Neurology.

[24]  W. Hickey,et al.  Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model , 2011, ASN neuro.

[25]  N. Heisterkamp,et al.  AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo , 2011, Blood cancer journal.

[26]  S. Gautam,et al.  Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[27]  S. Yang,et al.  In vivo Tracking of Transplanted Bone Marrow-Derived Mesenchymal Stem Cells in a Murine Model of Stroke by Bioluminescence Imaging. , 2010, Journal of Korean Neurosurgical Society.

[28]  E. Seifried,et al.  Bone marrow derived cells in the tumour microenvironment contain cells with primitive haematopoietic phenotype , 2010, Journal of cellular and molecular medicine.

[29]  C. Patlak,et al.  The MRI‐measured arterial input function resulting from a bolus injection of Gd‐DTPA in a rat model of stroke slightly underestimates that of Gd‐[14C]DTPA and marginally overestimates the blood‐to‐brain influx rate constant determined by Patlak plots , 2010, Magnetic resonance in medicine.

[30]  A. Karsan,et al.  Involvement of endothelial progenitor cells in tumor vascularization. , 2010, Microvascular research.

[31]  H. Vogel,et al.  Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. , 2010, The Journal of clinical investigation.

[32]  E. Kleinerman,et al.  Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas. , 2010, Cancer research.

[33]  Ali S. Arbab,et al.  Changes in Vascular Permeability and Expression of Different Angiogenic Factors Following Anti-Angiogenic Treatment in Rat Glioma , 2010, PloS one.

[34]  R. Kerbel,et al.  Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. , 2009, Cancer research.

[35]  E. Radaelli,et al.  Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. , 2009, Histology and histopathology.

[36]  Y. Meng,et al.  G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models , 2009, Proceedings of the National Academy of Sciences.

[37]  G. Ahn,et al.  Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature , 2009, Angiogenesis.

[38]  P. Wen,et al.  Novel anti-angiogenic therapies for malignant gliomas , 2008, The Lancet Neurology.

[39]  P. Wen,et al.  Antiangiogenic therapy in malignant gliomas , 2008, Current opinion in oncology.

[40]  R. Knight,et al.  Detection of migration of locally implanted AC133+ stem cells by cellular magnetic resonance imaging with histological findings , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[42]  N. Ferrara,et al.  Role of myeloid cells in tumor angiogenesis and growth. , 2008, Trends in cell biology.

[43]  J. Talmadge,et al.  Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. , 2008, Blood.

[44]  Arjan W Griffioen,et al.  A transgenic Tie2-GFP athymic mouse model; a tool for vascular biology in xenograft tumors. , 2008, Biochemical and biophysical research communications.

[45]  G. Ahn,et al.  Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. , 2008, Cancer cell.

[46]  S. Rafii,et al.  A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. , 2008, Cancer cell.

[47]  R. Knight,et al.  Identification of Variations in Blood-Brain Barrier Opening After Cerebral Ischemia by Dual Contrast-Enhanced Magnetic Resonance Imaging and T1sat Measurements , 2008, Stroke.

[48]  F. Peale,et al.  Bv8 regulates myeloid-cell-dependent tumour angiogenesis , 2007, Nature.

[49]  S. Kuroda,et al.  Role of SDF-1/CXCR4 system in survival and migration of bone marrow stromal cells after transplantation into mice cerebral infarct , 2007, Brain Research.

[50]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[51]  S. Rafii,et al.  The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. , 2007, Trends in immunology.

[52]  R. Tsien,et al.  Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. , 2007, Cancer research.

[53]  D. Scadden,et al.  Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. , 2006, Cancer research.

[54]  David J. Yang,et al.  The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. , 2006, Neuro-oncology.

[55]  Fan Zhang,et al.  Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes , 2006, Nature Medicine.

[56]  Alberto Mantovani,et al.  Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.

[57]  K. Camphausen,et al.  Orthotopic growth of human glioma cells quantitatively and qualitatively influences radiation-induced changes in gene expression. , 2005, Cancer research.

[58]  J. Parham,et al.  Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[59]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[60]  R. Weissleder,et al.  Bone marrow-derived lin(-)c-kit(+)Sca-1+ stem cells do not contribute to vasculogenesis in Lewis lung carcinoma. , 2005, Neoplasia.

[61]  M. Chopp,et al.  Analysis of Combined Treatment of Embolic Stroke in Rat with r-tPA and a GPIIb/IIIa Inhibitor , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[62]  M. Pesce,et al.  SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. , 2004, Blood.

[63]  B. Fingleton,et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.

[64]  Geoffrey C Gurtner,et al.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 , 2004, Nature Medicine.

[65]  Daniel J Brat,et al.  Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma , 2004, Laboratory Investigation.

[66]  Lian Li,et al.  Patlak plots of Gd‐DTPA MRI data yield blood–brain transfer constants concordant with those of 14C‐sucrose in areas of blood–brain opening , 2003, Magnetic resonance in medicine.

[67]  Raymond Sawaya,et al.  Optimizing outcomes with maximal surgical resection of malignant gliomas. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[68]  S. Rafii,et al.  Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.

[69]  S. Rafii,et al.  Mobilization of Endothelial and Hematopoietic Stem and Progenitor Cells by Adenovector‐Mediated Elevation of Serum Levels of SDF‐1, VEGF, and Angiopoietin‐1 , 2001, Annals of the New York Academy of Sciences.

[70]  Thomas N. Sato,et al.  Universal GFP reporter for the study of vascular development , 2000, Genesis.

[71]  Daniela Prayer,et al.  Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T. , 2012, Magnetic resonance imaging.

[72]  C. Chiang,et al.  Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model , 2012, Laboratory Investigation.

[73]  J.,et al.  The New England Journal of Medicine , 2012 .

[74]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[75]  M. Hendrix,et al.  Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. , 2007, The American journal of pathology.

[76]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[77]  G. Sledge,et al.  Can tumor angiogenesis be inhibited without resistance? , 2005, EXS.